Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
Merck
McKesson
Harvard Business School

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR REVLIMID


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Revlimid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
New Combination NCT00974233 ↗ Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed University of Wisconsin, Madison Phase 2 2009-10-01 The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Revlimid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00056160 ↗ CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Phase 3 2003-01-01 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
NCT00056160 ↗ CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Corporation Phase 3 2003-01-01 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
NCT00067743 ↗ A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed Celgene Corporation Phase 2 2003-08-01 This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)
NCT00087672 ↗ A Phase II Study of CC-5013 in Myelofibrosis Completed Celgene Corporation Phase 2 2004-07-01 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
NCT00087672 ↗ A Phase II Study of CC-5013 in Myelofibrosis Completed M.D. Anderson Cancer Center Phase 2 2004-07-01 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
NCT00093028 ↗ Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Completed University of Arkansas Phase 3 2004-01-01 The purpose of this study is - to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), - to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, - to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
NCT00098475 ↗ Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 3 2004-10-26 This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Revlimid

Condition Name

Condition Name for Revlimid
Intervention Trials
Multiple Myeloma 135
Chronic Lymphocytic Leukemia 33
Plasma Cell Myeloma 24
Lymphoma 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Revlimid
Intervention Trials
Multiple Myeloma 222
Neoplasms, Plasma Cell 217
Lymphoma 130
Leukemia 85
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Revlimid

Trials by Country

Trials by Country for Revlimid
Location Trials
Canada 132
Germany 60
Spain 59
France 59
Italy 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Revlimid
Location Trials
Texas 115
New York 109
California 106
Ohio 89
Florida 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Revlimid

Clinical Trial Phase

Clinical Trial Phase for Revlimid
Clinical Trial Phase Trials
Phase 4 5
Phase 3 56
Phase 2/Phase 3 4
[disabled in preview] 455
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Revlimid
Clinical Trial Phase Trials
Completed 222
Active, not recruiting 97
Terminated 91
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Revlimid

Sponsor Name

Sponsor Name for Revlimid
Sponsor Trials
Celgene Corporation 185
National Cancer Institute (NCI) 126
Celgene 104
[disabled in preview] 112
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Revlimid
Sponsor Trials
Other 511
Industry 475
NIH 129
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Harvard Business School
Mallinckrodt
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.